Bempegaldesleukin (BEMPEG/NKTR-214)

Bempegaldesleukin (BEMPEG/NKTR-214), Nektar's Lead Immuno-oncology Candidate

Bempegaldesleukin (BEMPEG/NKTR-214) is an immunostimulatory IL-2 cytokine prodrug which has been engineered to deliver a controlled, sustained, and preferential IL-2 pathway signal.

BEMPEG works by stimulating and expanding specific cancer-killing T-cells and natural killer (NK) cells without expanding intratumoral regulatory T cells, which dampen the immune response.

Bristol Myers Squibb and Nektar are actively advancing five registrational programs and one mid-stage program for BEMPEG in combination with nivolumab (OPDIVO®). The combination of BEMPEG and nivolumab leverages two clinically validated complementary IO pathways to unleash the full effect of the immune system against cancer.

BEMPEG is also being developed in partnership with Merck and SFJ Pharmaceuticals in a Phase 2/3 study in patients with metastatic head and neck cancer whose tumors express PD-L1.

Additional clinical studies evaluating BEMPEG in combination with other agents, such as cancer vaccines, are also underway. BEMPEG is also being evaluated as a potential treatment for mild COVID-19.

2021 European Society for Medical Oncology (ESMO) Congress

2021 Journal of Clinical Oncology

2021 Journal for ImmunoTherapy of Cancer

2021 World Congress of Melanoma (WCM)

2021 Annual Reviews

2020 World Conference on Lung Cancer Singapore

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2020 Cancer Discovery

2020 Future Medicine

2020 Genitourinary Cancers Symposium

Nature Communications – January 31, 2020

Kidney Cancer Journal

ESMO Immuno-Oncology Congress 2019

2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

2019 ASCO Annual Meeting

Cancer Discovery

AACR 2019

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

2019 Genitourinary Cancers Symposium (ASCO-GU)

SITC 2018

2018 ESMO Congress

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

SMI Immuno-Oncology Conference, London, UK

2018 ASCO Annual Meeting

2018 American Association for Cancer Research (AACR) Annual Meeting